News

Cepacol has introduced Cepacol Fizzlers, a single symptom sore throat relief product designed specifically for kids. Cepacol Fizzlers provides a solution for parents with children aged 5-12 suffering

Bristol-Myers Squibb has reached an agreement for the sale of its OTC assets in Asia Pacific (excluding China and Japan) to Taisho Pharmaceutical (Taisho). Under the terms of

GENova Biotherapeutics (GENova) has signed a collaboration agreement with Prime BioResearch (Prime BioResearch), the agreement is focused on how personalised medicine can be applied to cure cancer. The

AP Pharma has entered into a license and development agreement with Merial. The license agreement follows a successful research collaboration between the companies. Under the terms of the

Novartis has reported results from phase III trial showing QAB149 (indacaterol) significantly improves lung function and provides reduction in breathlessness compared to tiotropium, a current treatment option. QAB149

Wyeth Pharmaceuticals has reported the findings from a placebo-controlled phase 3 study of bazedoxifene 20mg extended to five years, which indicated a significant reduction versus placebo in new

HUYA Bioscience International has entered into a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). The agreement with GIBH is expected

Bavarian Nordic has signed a contract with the military of an undisclosed EU country for the delivery of a small order for Imvamune. The vaccines will be delivered

Merck Sharp & Dohme (MSD) has reported that Isentress (raltegravir) has been granted an expanded license from the European Union Commission for use in combination with other antiretroviral